We are live on
!
Find out more
TLP
Tri Locum Partners Portfolio holdings
AUM
$713M
1-Year Est. Return
68.92%
This Fund
S&P 500
This Quarter
Est. Return
+25.95%
1 Year Est. Return
+68.92%
3 Year Est. Return
+377.81%
5 Year Est. Return
+1,289.15%
10 Year Est. Return
–
AUM
$269M
AUM Growth
-$59.3M
(-18%)
Cap. Flow
-$75.4M
Cap. Flow
% of AUM
-28.03%
Top 10 Holdings %
Top 10 Hldgs %
55.66%
Holding
84
New
37
Increased
10
Reduced
12
Closed
25
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Johnson & Johnson
JNJ
|
+$20.6M |
| 2 |
Medtronic
MDT
|
+$13.8M |
| 3 |
Vertex Pharmaceuticals
VRTX
|
+$8.29M |
| 4 |
Legend Biotech
LEGN
|
+$7.63M |
| 5 |
SILK
Silk Road Medical, Inc. Common Stock
SILK
|
+$7.25M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Abbott
ABT
|
+$17.7M |
| 2 |
Regeneron Pharmaceuticals
REGN
|
+$17.5M |
| 3 |
Tandem Diabetes Care
TNDM
|
+$17M |
| 4 |
ARK Innovation ETF
ARKK
|
+$14.1M |
| 5 |
Sarepta Therapeutics
SRPT
|
+$12.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.08% |
| 2 | Financials | 0.24% |
| 3 | Industrials | 0.21% |
| 4 | Energy | 0.12% |
| 5 | Technology | 0.08% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
51
Cintas
CTAS
$81.5B
| $206K | 0.08% |
+1,656
| New | +$194K |
|
52
Berkshire Hathaway Class B
BRK.B
$1.11T
| $201K | 0.07% |
+588
| New | +$192K |
|
53
Kinder Morgan
KMI
$70.1B
| $178K | 0.07% |
+10,324
| New | +$175K |
|
54
Antero Midstream
AM
$10.4B
| $135K | 0.05% |
11,675
+561
| +5% | +$5.96K |
|
55
Rithm Capital
RITM
$5.66B
| $127K | 0.05% |
+13,531
| New | +$113K |
|
56
JetBlue
JBLU
$2.44B
| $123K | 0.05% |
+13,891
| New | +$101K |
|
57
Viatris
VTRS
$20.5B
| $104K | 0.04% |
+10,379
| New | +$99.1K |
|
58
Under Armour Class C
UA
$2.82B
| $77.9K | 0.03% |
+11,603
| New | +$85.2K |
|
59
Femasys
FEMY
$9.15M
| $57K | 0.02% |
5,585
-739
| -12% | -$12K |
|
60
AbbVie
ABBV
$430B
| – | – |
-49,213
| Closed | -$7.84M |
|
|
61
Abbott
ABT
$183B
| – | – |
-174,802
| Closed | -$17.7M |
|
|
AKRO
62
DELISTED
Akero Therapeutics
AKRO
| – | – |
-88,524
| Closed | -$3.39M |
|
63
Altimmune
ALT
$583M
| – | – |
-528,814
| Closed | -$2.23M |
|
|
APLS
64
DELISTED
Apellis Pharmaceuticals
APLS
| – | – |
-77,048
| Closed | -$5.08M |
|
|
65
ARK Innovation ETF
ARKK
$6.09B
| – | – |
-350,000
| Closed | -$14.1M |
|
66
Beam Therapeutics
BEAM
$2.85B
| – | – |
-107,230
| Closed | -$3.28M |
|
67
BioMarin Pharmaceuticals
BMRN
$11.7B
| – | – |
-76,070
| Closed | -$7.4M |
|
68
B2Gold
BTG
$5.18B
| – | – |
-19,076
| Closed | -$75.2K |
|
69
Evolus
EOLS
$398M
| – | – |
-160,269
| Closed | -$1.36M |
|
70
Evolent Health
EVH
$344M
| – | – |
-268,011
| Closed | -$8.7M |
|
71
Guardant Health
GH
$21.4B
| – | – |
-255,011
| Closed | -$5.98M |
|
72
Inspire Medical Systems
INSP
$1.82B
| – | – |
-17,523
| Closed | -$4.1M |
|
73
Merck
MRK
$318B
| – | – |
-114,242
| Closed | -$12.2M |
|
|
PGRE
74
DELISTED
Paramount Group
PGRE
| – | – |
-15,008
| Closed | -$68.4K |
|
75
uniQure
QURE
$3.06B
| – | – |
-227,273
| Closed | -$4.58M |
|
Similar funds
DCM
AMPWP
DCM
IWP
PCS
ACGDR
GEA
ECM
Tri Locum Partners's Q2 2023 Portfolio in Review
As of Q2 2023, Tri Locum Partners held 84 positions worth $269M, down 18% from $328M the previous quarter. Its ten largest holdings account for 56% of the portfolio.
Tri Locum Partners withdrew a net $75.4M in Q2 2023, closing 25 positions and reducing 12 holdings. Its most notable exit was Abbott, an estimated $17.7M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 96% a quarter earlier, followed by Financials and Industrials.
Against the trend, Tri Locum Partners opened a new position in Johnson & Johnson worth $21.1M.
- Tri Locum Partners's largest Q2 2023 buy was Johnson & Johnson: 127,362 shares worth $21.1M.
- Tri Locum Partners added most to Eli Lilly in Q2 2023, an estimated $4.16M increase.
- Tri Locum Partners's biggest Q2 2023 reduction was Regeneron Pharmaceuticals, cutting an estimated $17.5M.
- Tri Locum Partners fully exited Abbott in Q2 2023, selling an estimated $17.7M.
- Tri Locum Partners's ten largest holdings make up 56% of its $269M portfolio in Q2 2023.
- Tri Locum Partners opened 37 new positions and closed 25 in Q2 2023.
- Tri Locum Partners's portfolio value fell 18% quarter-over-quarter to $269M.
Based on Tri Locum Partners's 13F filing for Q2 2023, filed 14 Aug 2023.